I found the field of Pharmacology & Pharmacy; Chemistry very interesting. Saw the article Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators published in 2020. Recommanded Product: 2,6-Difluorobenzoic acid, Reprint Addresses Ma, B (corresponding author), Biogen, Med Chem, 225 Binney St, Cambridge, MA 02142 USA.. The CAS is 385-00-2. Through research, I have a further understanding and discovery of 2,6-Difluorobenzoic acid
Nrf2 is a transcription factor regulating expression of the Phase II Antioxidant Response and plays an important role in neuroprotection and detoxification. Nrf2 activation is inhibited by interaction with Keap1. Covalent Keap1 inhibitors such as dimethyl fumarate (DMF) and RTA-408 are either on the market or in late stage clinical trials which implies potential benefit of Nrf2 activation. Activation of Nrf2 by disrupting Nrf2-Keap1 interaction through a non-covalent small molecule is an attractive approach with the promise of greater selectivity. However, there are no known non-covalent Nrf2 activators with acceptable pharmacokinetic properties to test the hypothesis in vivo. Based on our early reported work, using structural-based design, followed by extensive SAR exploration, we have identified a novel series of non-covalent Nrf2 activators, with sub-nanomolar binding affinity on Keap1 and single digit nanomolar activity in an astrocyte assay. A representative analog shows excellent oral PK and good Nrf2-dependent gene inductions in kidney. These results provide a peripheral in vivo tool compound to validate the biology of non-covalent activation of Nrf2.
Recommanded Product: 2,6-Difluorobenzoic acid. About 2,6-Difluorobenzoic acid, If you have any questions, you can contact Ma, B; Lucas, B; Capacci, A; Lin, EYS; Jones, JH; Dechantsreiter, M; Enyedy, I; Marcotte, D; Xiao, GQ; Li, B; Richter, K or concate me.
Reference:
Isothiazole – Wikipedia,
,Isothiazole – ScienceDirect.com